Dapagliflozin + Saxagliptin in a Basal-bolus Insulin Treatment
Status:
Terminated
Trial end date:
2020-02-03
Target enrollment:
Participant gender:
Summary
To perform a study that investigates the effectiveness of adding the SGLT2 inhibitor
dapagliflozin + the dipeptidyl peptidase 4 (DPP-4) inhibitor saxagliptin vs placebo to revert
from a BBIT regimen to a BOT regimen in patients with type 2 diabetes.